Viral vector-based vaccines against SARS-CoV-2
Viral vectors have been frequently applied for vaccine development. It has also been the case for vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to tackle the coronavirus disease 2019 (COVID-19) pandemic. A multitude of different viral vectors have been mainly targetin...
Guardado en:
Autor principal: | Kenneth Lundstrom |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Open Exploration Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/21da190067fe46dd9fdb6c7b33606ee7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Development of an Inactivated Vaccine against SARS CoV-2
por: Shaikh Terkis Islam Pavel, et al.
Publicado: (2021) -
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity
por: Carlos del Fresno, et al.
Publicado: (2021) -
The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal
por: Eduardo Tosta
Publicado: (2021) -
RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
por: Hana M. Abdelzaher, et al.
Publicado: (2021) -
DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 1)
por: L. V. Cherenova, et al.
Publicado: (2017)